Ofatumumab-associated colitis: A case report

Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab. To report the first case of ofatumumab-associated colitis in MS and discuss its implications. Case report. A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation. This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.